LINCOLN, Neb. (AP) -- Nebraska will receive nearly $5 million from Abbott Laboratories to settle concerns that it improperly marketed its anti-seizure drug Depakote.
Nebraska's Medicaid program will receive $3.7 million, and $1.2 million will go to the state's consumer settlement fund.
Depakote is an anti-seizure and mood-stabilizing drug that's prescribed for bipolar disorder. Abbott admitted marketing Depakote for unapproved uses including dementia and schizophrenia in violation of FDA rules.
Nationally, the case includes a criminal fine and forfeiture of $700 million and civil settlements with the federal government and states totaling $800 million.
The national settlement was announced Monday.
